Table 2.
Factor |
Model 1 |
Model 2 |
||
---|---|---|---|---|
Hazard ratio (95% CI) | p-value | Hazard ratio (95% CI) | p-value | |
Age |
0.99 (0.94–1.03) |
0.49 |
1.01 (0.95–1.07) |
0.78 |
PSA |
1.09 (1.02–1.17) |
0.011 |
1.08 (0.96–1.22) |
0.22 |
Gleason |
1.02 (0.72–1.46) |
0.90 |
1.55 (0.73–3.27) |
0.25 |
Clinical T stage |
1.32 (0.59–2.94) |
0.49 |
1.64 (0.48–5.55) |
0.43 |
ADT |
0.55 (0.31–0.99) |
0.045 |
0.20 (0.07–.057) |
0.002 |
Technique |
0.13 (0.07–0.23) |
<0.001 |
----------- |
|
BED | ----------- | 0.987 (0.981–0.993) | <0.001 |
PSA, Prostate-specific antigen; ADT, Androgen deprivation therapy; BED, Biological effective dose.